In this compelling episode of Global Market Bulletin TV, host Leyla Gulen sits down for an exclusive and in-depth conversation with Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics (NASDAQ:VIRI). As a development-stage biotechnology company pioneering novel combination antiviral therapies, Virios Therapeutics is working to change the treatment landscape for some of the most misunderstood and debilitating chronic illnesses — including fibromyalgia, Long COVID, and other complex viral-triggered disorders.
During this deeply informative interview, Duncan outlines the company’s scientific approach and the immense unmet need driving Virios Therapeutics’ mission. He provides an update on the company’s pivotal request for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), a significant step toward moving IMC-1, Virios’ patented antiviral combination therapy, into Phase 3 development for fibromyalgia. The meeting, targeted for mid-March 2023, will play a central role in determining the regulatory and clinical pathway for this potentially groundbreaking therapy.
Duncan also shares exciting details about ongoing enrollment in Intervene Immune’s Long COVID exploratory trial, where IMC-1 and IMC-2 are being evaluated for their potential to address a wide range of persistent symptoms linked to viral reactivation. These include fatigue, autonomic instability, cognitive deficits, chronic pain, and sleep disturbances — symptoms that continue to affect millions worldwide following COVID-19 infection.
With decades of experience leading drug development, commercial launches, and multinational pharmaceutical operations, Duncan brings unparalleled expertise to the discussion. His insights go beyond clinical data — offering viewers a strategic look at IR pathways, scientific rationale, and the therapeutic promise behind Virios’ antiviral approach.
This episode is invaluable for biotech investors, clinicians, researchers, and anyone following the evolving science behind fibromyalgia, Long COVID, and functional somatic syndromes. Virios Therapeutics’ work challenges long-held assumptions about chronic illness and proposes a bold, virus-targeted approach backed by emerging evidence and strong biological rationale.
Be sure to Subscribe to Global Market Bulletin TV and activate notifications to stay ahead of industry-shaping interviews, CEO insights, and breakthrough biotech conversations.
About Greg Duncan
Chairman & CEO – Virios Therapeutics
Greg Duncan is a seasoned biotechnology executive with an extensive track record of leading drug development programs, raising significant investment capital, and bringing innovative therapies to global markets. Before joining Virios Therapeutics, Duncan served as President & CEO of Celtaxsys, where he advanced novel anti-inflammatory compounds for rare diseases.
Earlier in his career, Duncan spent over 20 years in senior leadership roles at Pfizer, including President of Latin America Operations, where he oversaw $2 billion in revenue, and Senior Vice President of Marketing. His teams played major roles in the commercial success of globally recognized treatments such as Lipitor, Zoloft, Viagra, Celebrex, and Aricept.
He has also held director or advisory positions with Biotie Therapeutics, the American Psychiatric Foundation, and multiple biotech trade associations. Duncan holds an MBA from Emory University and a degree in Economics from SUNY Albany, complementing his leadership experience with deep industry, financial, and clinical development expertise.
CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.
About Virios Therapeutics (NASDAQ: VIRI)
Virios Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative antiviral treatments for chronic diseases believed to be triggered or worsened by latent herpesvirus activation. The company focuses on conditions such as fibromyalgia, Long COVID, chronic fatigue syndrome, irritable bowel syndrome, and other functional somatic disorders — all of which are characterized by fluctuating symptoms and limited therapeutic options.
Virios’ lead candidate, IMC-1, is a patented fixed-dose combination therapy consisting of famciclovir and celecoxib, designed to synergistically inhibit herpesvirus replication and reduce virus-driven inflammatory responses. The FDA has granted Fast Track Designation to IMC-1 for fibromyalgia, underscoring its potential to address a major unmet medical need.
The company’s second development program, IMC-2 (valacyclovir + celecoxib), is being explored as a therapeutic option for Long COVID/PASC symptoms, leveraging the same antiviral-anti-inflammatory mechanism of action.
Virios Therapeutics remains committed to advancing IMC-1 into Phase 3 development, focusing on newly diagnosed fibromyalgia patients to optimize therapeutic outcomes and accelerate the regulatory path forward.
READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.
